Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates

Clinical Trial & Drug Development - Vertex's next-generation pain drug, VX993, failed in a phase 2 trial, leading to the discontinuation of its development [1] - Pain management is highlighted as an increasingly significant area for Vertex [1] - Javics, a drug approved earlier in the year, is showing a stronger launch than anticipated in the previous quarter [2] Leadership Transition - David Oler, the chief scientific officer, will be retiring next year [2] - The current head of research will be promoted to chief scientific officer upon Oler's departure [3] Stock Performance - Vertex's stock is down 11% [3]